
Carolyn J Presley, Mhs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3644282/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunology, Immunotherapy, 2022, 71, 1157-1165.	2.0	12
2	Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. Journal of the American Geriatrics Society, 2022, 70, 136-149.	1.3	10
3	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	1.1	2
4	Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clinical Lung Cancer, 2022, 23, 345-355.	1.1	13
5	Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non–Small Cell Lung Cancer Versus Community Controls. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 118-125.	2.3	6
6	Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With a New Thoracic Malignancy. Frontiers in Oncology, 2022, 12, 835881.	1.3	5
7	Polypharmacy in older adults with cancer undergoing radiotherapy: A review. Journal of Geriatric Oncology, 2022, 13, 778-783.	0.5	5
8	Aggressive End-of-Life Care in the Veterans Health Administration versus Fee-for-Service Medicare among Patients with Advanced Lung Cancer. Journal of Palliative Medicine, 2022, 25, 932-939.	0.6	2
9	A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial. Frontiers in Oncology, 2022, 12, 835582.	1.3	6
10	Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100334.	0.6	4
11	Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Frontiers in Immunology, 2022, 13, 779691.	2.2	100
12	Illness perception profiles and psychological and physical symptoms in newly diagnosed advanced non-small cell lung cancer Health Psychology, 2022, 41, 379-388.	1.3	10
13	Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non–Small Cell Lung Cancer. JAMA Network Open, 2022, 5, e2221626.	2.8	11
14	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 861-874.	1.1	6
15	Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. Journal of Palliative Medicine, 2021, 24, 195-204.	0.6	3
16	End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Supportive Care in Cancer, 2021, 29, 3921-3932.	1.0	5
17	The aging microbiome and response to immunotherapy: Considerations for the treatment of older adults with cancer. Journal of Geriatric Oncology, 2021, 12, 985-989.	0.5	2
18	Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunology, Immunotherapy, 2021, 70, 2761-2769.	2.0	7

CAROLYN J PRESLEY, MHS

#	Article	IF	CITATIONS
19	Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment. Current Medical Research and Opinion, 2021, 37, 643-653.	0.9	5
20	Substance Abuse Risk and Medication Monitoring in Patients with Advanced Lung Cancer Receiving Palliative Care. Journal of Pain and Palliative Care Pharmacotherapy, 2021, 35, 91-99.	0.5	3
21	Too Many Appointments: Assessing Provider and Nursing Perception of Barriers to Referral for Outpatient Palliative Care. Palliative Medicine Reports, 2021, 2, 137-145.	0.4	8
22	Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer. JCO Oncology Practice, 2021, 17, e848-e858.	1.4	13
23	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. Journal of Geriatric Oncology, 2021, 12, 813-819.	0.5	23
24	Care Disparities Across the Health Care Continuum for Older Adults: Lessons From Multidisciplinary Perspectives. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e215-e224.	1.8	9
25	Immunotherapy in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2115-2127.	0.8	33
26	Bayesian structural time series for biomedical sensor data: A flexible modeling framework for evaluating interventions. PLoS Computational Biology, 2021, 17, e1009303.	1.5	8
27	Feasibility of implementing an exercise intervention in older adults with hematologic malignancy. Journal of Geriatric Oncology, 2021, , .	0.5	2
28	Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1055-1062.	2.3	15
29	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. JAMA Oncology, 2021, 7, 1856.	3.4	74
30	Evaluating the Carg Chemotherapy Toxicity Calculator Among Older Adults Newly Diagnosed with Hematologic Malignancy. Blood, 2021, 138, 1931-1931.	0.6	1
31	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. JAMA Network Open, 2021, 4, e2139593.	2.8	55
32	Mentoring pearls of wisdom: Lessons learned by mentees of Arti Hurria, MD. Journal of Geriatric Oncology, 2020, 11, 335-337.	0.5	1
33	Patterns of pain medication use associated with reported pain interference in older adults with and without cancer. Supportive Care in Cancer, 2020, 28, 3061-3072.	1.0	9
34	A story of connection: A tribute to Arti Hurria, MD. Journal of Geriatric Oncology, 2020, 11, 164-165.	0.5	0
35	Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms. Lung Cancer, 2020, 145, 195-204.	0.9	22
36	Patterns of Symptom Management Medication ReceiptÂatÂEnd-of-Life Among Medicare BeneficiariesÂWithÂLung Cancer. Journal of Pain and Symptom Management, 2020, 59, 767-777.e1.	0.6	13

#	Article	IF	CITATIONS
37	Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice, 2020, 16, e1355-e1370.	1.4	18
38	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2403-2408.	2.0	10
39	Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the 2020 American Society of Clinical Oncology (ASCO) annual meeting. Journal of Geriatric Oncology, 2020, 11, 1324-1328.	0.5	13
40	Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer, 2020, 20, 383.	1.1	45
41	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e207205.	2.8	19
42	Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer. Journal of Geriatric Oncology, 2020, 11, 960-968.	0.5	18
43	Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration. Journal of Palliative Medicine, 2020, 23, 1038-1044.	0.6	9
44	<p>Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects</p> . Patient Preference and Adherence, 2020, Volume 14, 927-937.	0.8	39
45	Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice. BMC Geriatrics, 2020, 20, 231.	1.1	36
46	Multidisciplinary telemedicine and the importance of being seen. Journal of Geriatric Oncology, 2020, 11, 1349-1351.	0.5	16
47	Patterns of physical and mental health well-being in older female cancer survivors Journal of Clinical Oncology, 2020, 38, 173-173.	0.8	1
48	Respiratory Organ Aging and Cancer. , 2020, , 215-244.		0
49	Effect of Geriatric Assessment and Intervention on Overall Survival Among Older Adults with Hematologic Malignancies. Blood, 2020, 136, 31-32.	0.6	2
50	Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults. Journal of Geriatric Oncology, 2019, 10, 60-67.	0.5	17
51	Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2541-2546.	1.2	93
52	Geriatric oncology research at the 2019 American Geriatrics Society (AGS) annual meeting: Joint perspectives from the Young International Society of Geriatric Oncology (SIOG) and AGS Cancer and Aging Special Interest Group. Journal of Geriatric Oncology, 2019, 10, 994-997.	0.5	2
53	Prioritization of Patient-Reported Outcomes by Women With Metastatic Breast Cancer. JCO Clinical Cancer Informatics, 2019, 3, 1-3.	1.0	2
54	Value-Added Decisions in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 122-131.	1.8	5

CAROLYN J PRESLEY, MHS

#	Article	IF	CITATIONS
55	Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncology, 2019, 5, 1028.	3.4	73
56	Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. Journal of Geriatric Oncology, 2019, 10, 669-672.	0.5	8
57	Addressing New Diagnostic and Treatment Challenges Associated With a New Age of CancerÂTreatment. Annals of Emergency Medicine, 2019, 73, 88-90.	0.3	8
58	Improving biobehavioral outcomes with progressive muscle relaxation in patients with advanced lung cancer Journal of Clinical Oncology, 2019, 37, 292-292.	0.8	2
59	Restoring Functional Deficits in Older Adults with Hematologic Malignancy. Blood, 2019, 134, 4776-4776.	0.6	Ο
60	Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting. JAMA - Journal of the American Medical Association, 2018, 320, 469.	3.8	110
61	Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology, 2018, 4, e180798.	3.4	86
62	Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy. Blood, 2018, 132, 4870-4870.	0.6	1
63	Undertreated pain: Trends over time for older adults with and without cancer Journal of Clinical Oncology, 2018, 36, 15-15.	0.8	2
64	Patterns and determinants of pain and emotional distress in older adults with cancer: A population based study Journal of Clinical Oncology, 2018, 36, 10105-10105.	0.8	0
65	Undertreated emotional distress in older adults with cancer Journal of Clinical Oncology, 2018, 36, 165-165.	0.8	2
66	Information Needs of Older Women With Early-Stage Breast Cancer When Making Radiation Therapy Decisions. International Journal of Radiation Oncology Biology Physics, 2017, 98, 733-740.	0.4	40
67	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Current Oncology Reports, 2017, 19, 62.	1.8	20
68	Treatment Burden of Medicare Beneficiaries With Stage I Non–Small-Cell Lung Cancer. Journal of Oncology Practice, 2017, 13, e98-e107.	2.5	26
69	Caring for the Older Population With Advanced Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 587-596.	1.8	5
70	Gaps in nutritional research among older adults with cancer. Journal of Geriatric Oncology, 2016, 7, 281-292.	0.5	47
71	Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. Journal of Geriatric Oncology, 2016, 7, 293-304.	0.5	58
72	Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Right Treatment for the Right Patient. Journal of Clinical Oncology, 2016, 34, 1438-1442.	0.8	16

#	Article	IF	CITATIONS
73	The Treatment of Advanced Lung Cancer in the Elderly. Cancer Journal (Sudbury, Mass), 2015, 21, 392-397.	1.0	11
74	A new approach to understanding racial disparities in prostate cancer treatment. Journal of Geriatric Oncology, 2013, 4, 1-8.	0.5	37
75	Reply to L.W. Cuttino et al. Journal of Clinical Oncology, 2013, 31, 2227-2229.	0.8	2
76	Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal of Clinical Oncology, 2012, 30, 4302-4307.	0.8	67
77	The Relationship Between Clinical Benefit and Receipt of Curative Therapy for Prostate Cancer. Archives of Internal Medicine, 2012, 172, 362.	4.3	10